Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CDC25A | P30304 | 6/20 | 0.34 |
| ▸ | CDC25B | P30305 | 6/20 | 0.34 |
| ▸ | CDC25C | P30307 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31406624 | 1.00 | PPARG (0.37) | PPARGACHEBACE1CDC25ACDC25B | |
| SCHEMBL31406633 | 0.98 | PPARG (0.35) | PPARGACHEBACE1CDC25ACDC25B | |
| SCHEMBL10504915 | 0.92 | CTRC (0.34) | PPARG | |
| SCHEMBL2107621 | 0.81 | CTRC (0.39) | PPARGMAPT | |
| SCHEMBL1080657 | 0.80 | PPARG (0.35) | PPARGACHEBACE1CDC25ACDC25B | |
| SCHEMBL10701592 | 0.78 | PPARG (0.35) | PPARGACHEBACE1CDC25ACDC25B | |
| SCHEMBL7137786 | 0.78 | PPARG (0.35) | PPARGACHEBACE1CDC25ACDC25B | |
| SCHEMBL7509115 | 0.77 | PPARG (0.37) | PPARGACHEBACE1CDC25ACDC25B | |
| SCHEMBL2193271 | 0.74 | PPARG (0.35) | PPARGACHEBACE1CDC25ACDC25B | |
| SCHEMBL7354784 | 0.74 | CTRC (0.35) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448400-B2 | KRAS G12D modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250136621-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250109147-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-04-03 | — | — | US | disclosed |
| WO-2025054530-A1 | PYRIMIDINE-CONTAINING POLYCYCLIC DERIVATIVES AS KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448400-B2 | KRAS G12D modulating compounds | KRAS, NRAS, HRAS | PPARG 614/4885ACHE 4876/4885BACE1 2658/4885 |
| US-20250136621-A1 | KRAS G12D MODULATING COMPOUNDS | KRAS, NRAS, HRAS | PPARG 614/4885ACHE 4876/4885BACE1 2658/4885 |
| US-20250109147-A1 | KRAS G12D MODULATING COMPOUNDS | KRAS, NRAS, HRAS | PPARG 614/4885ACHE 4876/4885BACE1 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.